Richard Bungay, an experienced biopharma executive, has been appointed chief financial officer of Diurnal Group Plc, a UK-based company developing treatments for chronic endocrine conditions. Mr Bungay was most recently CFO and chief operating officer of Mereo BioPharma Group Plc where he managed the introduction of the company’s shares to the AIM market in London. He has also served as CFO at Chroma Therapeutics Ltd, Glide Technologies Ltd and Verona Pharma Plc.
Mr Bungay qualified as a charter accountant with Deloitte in 1993.
Diurnal announced the appointment on 12 January 2017.
Copyright 2017 Evernow Publishing Ltd